We are a partnership across industry, academia, healthcare, government, patients and the public committed to rapidly discover, implement and commercialize ‘omics-based biomarker tests that address unmet medical needs.
Our biomarker programs harness the power of clinical, molecular and computational science to develop biomarker tests to better predict, diagnose, manage and treat a range of disease indications.
We offer flexible partnering options that provide organizations around the world with support in artificial intelligence, ‘-omics science and various biomarker workflows that will expedite diagnostic and drug development efforts.
We are committed to supporting the healthcare and research community during the COVID19 crisis through redeployment of our resources.
Click HERE to read more about how we can help.
2021 Yang C, Zhao H, Tebbutt SJ. Balancing the Risks and Benefits of COVID-19 Vaccination for Pregnant Women and Their Children. Frontiers, 1 Jan. 1AD, https://www.frontiersin.org/articles/10.3389/fimmu.2021.748456/full. Yang C, Zhao H, Tebbutt SJ. Long-Term Effects on Survivors with COVID-19. The Lancet, vol.Read more